Back to Search
Start Over
Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 3 trial
Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 3 trial
- Source :
- Diabetes, Obesity and Metabolism. 25:1229-1240
- Publication Year :
- 2023
- Publisher :
- Wiley, 2023.
-
Abstract
- To evaluate the efficacy and safety of janagliflozin, a selective inhibitor of the renal sodium-glucose cotransporter-2, as monotherapy in drug-naive Chinese patients with type 2 diabetes mellitus (T2DM).This phase 3 trial included a 24-week, multicenter, randomized, double-blind, placebo-controlled period, followed by a 28-week extension period. 432 patients with HbAAt Week 24, the placebo-adjusted LS mean changes of HbAJanagliflozin 25 mg and 50 mg monotherapy once-daily effectively improved glycemic control, reduced body weight and blood pressure, improved HDL-C and insulin sensitivity, and was generally well-tolerated.NCT03811548 This article is protected by copyright. All rights reserved.
- Subjects :
- Endocrinology
Endocrinology, Diabetes and Metabolism
Internal Medicine
Subjects
Details
- ISSN :
- 14631326 and 14628902
- Volume :
- 25
- Database :
- OpenAIRE
- Journal :
- Diabetes, Obesity and Metabolism
- Accession number :
- edsair.doi.dedup.....242ed4d12dabf2fa8875b3b2e705e120
- Full Text :
- https://doi.org/10.1111/dom.14971